

Figure S1. Cytotoxic response to treatment with CDK4/6 inhibitor PD and PI3K inhibitor BYL on NB cell lines. Cytotoxic response of SK-N-AS treated with PD (A), BYL (B) and combination of PD and BYL (C), cytotoxic response of SK-N-BE(2)-C treated with PD (D), BYL (E) and combination of PD and BYL (F), cytotoxic response of SK-N-DZ treated with PD (G), BYL (H) and combination of PD and BYL (I), cytotoxic response of SK-N-FI treated with PD (J), BYL (K) and combination of PD and BYL (L) and cytotoxic response of SK-N-SH treated with PD (M), BYL (N) and combination of PD and BYL (O) was measured every 2 h up to 72 h after the treatment. NB, neuroblastoma; BYL, BYL719; PD, PD-0332991; CDK4/6, cyclin-dependent kinase-4/6; PI3K, phosphoinositide 3-kinase.




Figure S2. Cytotoxic response of neuroblastoma cell lines to treatment with WEE1 G2 checkpoint kinase MK and PARP inhibitor BMN. Cytotoxic response of SK-N-AS treated with MK (A), BMN (B) and combination of MK and BMN (C), cytotoxic response of SK-N-BE(2)-C treated with MK (D), BMN (E) and combination of MK and BMN (F), cytotoxic response of SK-N-DZ treated with (G) MK (G), BMN (H) and combination of MK and BMN (I), cytotoxic response of SK-N-FI treated with MK (J), BMN (K) and combination of MK and BMN (L) and cytotoxic response of SK-N-SH treated with MK (M), BMN (N) and combination of MK and BMN (O) was measured every 2 h up to 72 h after the treatment. BMN, BMN673; MK, MK-1775; PARP, poly-ADP-ribose-polymerase.




Figure S3. Apoptosis of neuroblastoma cell lines following treatment with PD and BYL. Apoptosis of SK-N-AS treated with PD (A), BYL (B) and combination of PD and BYL (C), apoptosis of SK-N-BE(2)-C treated with PD (D), BYL (E) and combination of PD and BYL (F), apoptosis of SK-N-DZ treated with PD (G), BYL (H) and combination of PD and BYL (I), apoptosis of SK-N-FI treated with PD (J), BYL (K) and combination of PD and BYL (L) and apoptosis of SK-N-SH treated with PD (M), BYL (N) and combination of PD and BYL (O) was measured every 2 h up to 72 h after the treatment. BYL, BYL719; PD, PD-0332991.




Figure S4. Apoptosis of neuroblastoma cell lines following treatment with MK and BMN. Apoptosis of SK-N-AS treated with MK (A), BMN (B) and combination of MK and BMN (C), apoptosis of SK-N-BE(2)-C treated with MK (D), BMN (E) and combination of MK and BMN (F), apoptosis of SK-N-DZ treated with MK (G), BMN (H) and combination of MK and BMN (I), apoptosis of SK-N-FI treated with MK (J), BMN (K) and combination of MK and BMN (L) and apoptosis of SK-N-SH treated with MK (M), BMN (N) and combination of MK and BMN (O) was measured every 2 h up to 72 h after the treatment. BMN, BMN673; MK, MK-1775; PARP, poly-ADP-ribose-polymerase.

